{"id":541,"date":"2018-09-12T09:00:00","date_gmt":"2018-09-12T09:00:00","guid":{"rendered":"https:\/\/isosolution-v2.staging.xiyx.ai\/news\/first-in-human-study-of-177lu-eb-psma-617-in-patients-with-metastatic-castration-resistant-prostate-cancer\/"},"modified":"2018-09-12T09:00:00","modified_gmt":"2018-09-12T09:00:00","slug":"first-in-human-study-of-177lu-eb-psma-617-in-patients-with-metastatic-castration-resistant-prostate-cancer","status":"publish","type":"iso_news","link":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/news\/first-in-human-study-of-177lu-eb-psma-617-in-patients-with-metastatic-castration-resistant-prostate-cancer\/","title":{"rendered":"Estudio primero en humano de 177Lu-EB-PSMA-617 en pacientes con c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n metast\u00e1sico"},"content":{"rendered":"<p>Este primer estudio humano demostr\u00f3 que 177Lu-EB-PSMA-617 ten\u00edan una acumulaci\u00f3n m\u00e1s alta en mCRPC y que la dosis baja de im\u00e1genes parece ser eficaz en el tratamiento de tumores con dosis altas de 68Ga-PSMA-617. Las tomas elevadas de 177Lu-EBPSMA-617 en ri\u00f1ones y m\u00e9dula \u00f3sea roja fueron bien toleradas en la dosis baja administrada. Se justifican nuevas investigaciones con mayor dosis y frecuencia de administraci\u00f3n. <a href=\"https:\/\/isosolutions.com\/first-in-human-study-of-177lu-eb-psma-617-in-patients-with-metastatic-castration-resistant-prostate-cancer\/\"><span aria-label=\"Seguir leyendo Estudio de primera en humana de 177Lu-EB-PSMA-617 en pacientes con c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n metast\u00e1sico\">(m\u00e1s...)<\/span><\/a><\/p>\n<\/p><\/div>\n<p>Etiquetas: <a href=\"https:\/\/isosolutions.com\/news-tag\/isosolutions\/\" rel=\"tag\">isoSolutions<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/lu-177\/\" rel=\"tag\">Lu-177<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/radiochemicals\/\" rel=\"tag\">Radioqu\u00edmicos<\/a> <a href=\"https:\/\/isosolutions.com\/news-tag\/research\/\" rel=\"tag\">Investigaci\u00f3n<\/a><\/p>\n<\/p><\/div>","protected":false},"excerpt":{"rendered":"<p>This first-in-human study demonstrated that 177Lu-EB-PSMA-617 had higher accumulation in mCRPC and that low imaging dose appears to be effective in treating tumors with high 68Ga-PSMA-617 uptakes.\u2026<\/p>","protected":false},"featured_media":567,"template":"","iso_news_section":[43],"class_list":["post-541","iso_news","type-iso_news","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news\/541","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news"}],"about":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/types\/iso_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/media\/567"}],"wp:attachment":[{"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/media?parent=541"}],"wp:term":[{"taxonomy":"iso_news_section","embeddable":true,"href":"https:\/\/isosolution-v2.staging.xiyx.ai\/es\/wp-json\/wp\/v2\/iso_news_section?post=541"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}